HRP20130052T1 - Lijeäśenje respiratorne bolesti - Google Patents
Lijeäśenje respiratorne bolesti Download PDFInfo
- Publication number
- HRP20130052T1 HRP20130052T1 HRP20130052AT HRP20130052T HRP20130052T1 HR P20130052 T1 HRP20130052 T1 HR P20130052T1 HR P20130052A T HRP20130052A T HR P20130052AT HR P20130052 T HRP20130052 T HR P20130052T HR P20130052 T1 HRP20130052 T1 HR P20130052T1
- Authority
- HR
- Croatia
- Prior art keywords
- glitazone
- pulmonary
- disease
- asthma
- inflammatory
- Prior art date
Links
- 208000023504 respiratory system disease Diseases 0.000 title claims description 9
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 11
- 208000006673 asthma Diseases 0.000 claims 8
- 230000002757 inflammatory effect Effects 0.000 claims 7
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010006451 bronchitis Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960005095 pioglitazone Drugs 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 229960004586 rosiglitazone Drugs 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000003434 antitussive agent Substances 0.000 claims 2
- 229940124584 antitussives Drugs 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 239000000168 bronchodilator agent Substances 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003172 expectorant agent Substances 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- 229940066491 mucolytics Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 2
- 201000004193 respiratory failure Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
LIJEČENJE RESPIRATORNE BOLESTI
Claims (9)
1. Glitazon za uporabu u liječenju upalne respiratorne bolesti pulmonalnom administracijom sa inhalacijom, naznačen time da se inhalirani glitazon sastoji od barem 95% težinski 5R konfiguracije i manje od 5% težinski 5S konfiguracije, te pri čemu navedeni glitazon je pioglitazon ili rosiglitazon.
2. Glitazon za uporabu prema zahtjevu 1, naznačen time da je navedena upalna respiratorna bolest odabrana od blage astme, srednje astme, teške astme, astme otporne na steroide, bronhitisa, kronične opstruktivne plućne bolesti (KOPB), cistične fibroze, plućnog edema, plućne embolije, upale pluća, plućne sarkoidoze, silikoze, plućne fibroze, respiratornog zatajenja, akutnog respiratornog distresnog sindroma, emfizema, kroničnog bronhitisa, tuberkuloze, te raka pluća.
3. Glitazon za uporabu prema zahtjevu 1, naznačen time da navedena upalna respiratorna bolest je kronična opstruktivna plućna bolest.
4. Uporaba glitazona za dobivanje lijeka za liječenje upalne respiratorne bolesti pulmonalnom administracijom sa inhalacijom naznačena time da se sadržaj glitazona u lijeku sastoji od barem 95% težinski 5R konfiguracije i manje od 5% težinski 5S konfiguracije, te pri čemu navedeni glitazon je pioglitazon ili rosiglitazon.
5. Uporaba prema zahtjevu 4, naznačena time da je navedena upalna respiratorna bolest odabrana od blage astme, srednje astme, teške astme, astme otporne na steroide, bronhitisa, kronične opstruktivne plućne bolesti (KOPB), cistične fibroze, plućnog edema, plućne embolije, upale pluća, plućne sarkoidoze, silikoze, plućne fibroze, respiratornog zatajenja, akutnog respiratornog distresnog sindroma, emfizema, kroničnog bronhitisa, tuberkuloze, te raka.
6. Uporaba prema zahtjevu 4, naznačena time da navedena upalna respiratorna bolest je kronična opstruktivna plućna bolest.
7. Farmaceutski pripravak prilagođena za pulmonalnu administraciju sa inhalacijom, te navedeni pripravak sadrži glitazon i jedan ili više farmaceutski prihvatljivih nosača i/ili pomoćnih tvari, te pri čemu sadržaj glitazona u pripravku iznosi barem 95% težinski 5R konfiguracije i manje od 5% težinski 5S konfiguracije, te pri čemu navedeni glitazon je pioglitazon ili rosiglitazon.
8. Farmaceutski pripravak prema zahtjevu 7 naznačen time da dodatno sadrži jedno ili više drugih terapeutskih sredstava koja su odabrana od anti-upalnih sredstava, bronhodilatora, mukolitičkih sredstava, antitusivnih sredstava, inhibitora leukotriena, te antibiotika.
9. Komplet za liječenje upalnih respiratornih poremećaja kod subjekta, naznačen time da komplet sadrži jedan oblik doziranja koji sadrži pripravak prema zahtjevu 7 i drugi oblik doziranja koji sadrži drugo terapeutsko sredstvo koje je odabrano od anti-upalnih sredstava, bronhodilatora, mukolitičkih sredstava, antitusivnih sredstava, inhibitora leukotriena i antibiotika.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0814488A GB0814488D0 (en) | 2008-08-07 | 2008-08-07 | Respiratory disease treatment |
| GB0823568A GB0823568D0 (en) | 2008-12-24 | 2008-12-24 | Respiratory disease treatment |
| PCT/GB2009/001920 WO2010015818A1 (en) | 2008-08-07 | 2009-08-05 | Respiratory disease treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130052T1 true HRP20130052T1 (hr) | 2013-02-28 |
Family
ID=41202662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130052AT HRP20130052T1 (hr) | 2008-08-07 | 2013-01-22 | Lijeäśenje respiratorne bolesti |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2222272B1 (hr) |
| JP (1) | JP5689797B2 (hr) |
| CN (1) | CN102170864B (hr) |
| AU (1) | AU2009279077C1 (hr) |
| BR (1) | BRPI0917567A2 (hr) |
| CA (1) | CA2733440C (hr) |
| CY (1) | CY1113744T1 (hr) |
| DK (1) | DK2222272T3 (hr) |
| EA (1) | EA019339B1 (hr) |
| ES (1) | ES2399179T3 (hr) |
| GB (1) | GB2465897B (hr) |
| HK (1) | HK1156501A1 (hr) |
| HR (1) | HRP20130052T1 (hr) |
| IL (1) | IL210959A0 (hr) |
| MX (1) | MX2011001418A (hr) |
| NZ (1) | NZ590774A (hr) |
| PL (1) | PL2222272T3 (hr) |
| PT (1) | PT2222272E (hr) |
| SI (1) | SI2222272T1 (hr) |
| SM (1) | SMT201300007B (hr) |
| WO (1) | WO2010015818A1 (hr) |
| ZA (1) | ZA201100750B (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| GB0913672D0 (en) | 2009-08-05 | 2009-09-16 | Argenta Discovery Ltd | Glitazones |
| WO2011084453A1 (en) | 2009-12-15 | 2011-07-14 | Metabolic Solutions Development Company | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases |
| GB2477540A (en) * | 2010-02-05 | 2011-08-10 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| WO2011098746A1 (en) * | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) * | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) * | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB2477743A (en) * | 2010-02-10 | 2011-08-17 | Argenta Therapeutics Ltd | Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds |
| AU2014249168B2 (en) * | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
| KR20150127245A (ko) | 2013-03-14 | 2015-11-16 | 켈탁시스, 인코퍼레이티드 | 류코트라이엔 a4 가수분해효소의 저해제 |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| CA3020161A1 (en) * | 2016-04-05 | 2017-10-12 | Immune Sensor, Llc | Cgas antagonist compounds |
| KR101841589B1 (ko) * | 2016-12-02 | 2018-03-23 | 주식회사 종근당 | 로베글리타존을 유효성분으로 포함하는 섬유증 예방 또는 치료용 약학적 조성물 |
| EP3787618A4 (en) | 2018-05-04 | 2022-05-04 | Cirius Therapeutics, Inc. | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES |
| EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE |
| AU2020218272A1 (en) | 2019-02-08 | 2021-09-02 | United States Government As Represented By The Department Of Veterans Affairs | Growth hormone-releasing hormone antagonists and uses thereof |
| CA3143758A1 (en) * | 2019-07-18 | 2021-01-21 | University Of Miami | Ghrh antagonists for use in a method of treating sarcoidosis |
| US20210315937A1 (en) * | 2020-04-08 | 2021-10-14 | University Of South Florida | Methods of treating inflammation |
| WO2021212054A1 (en) * | 2020-04-17 | 2021-10-21 | Cirius Therapeutics, Inc. | Methods and compositions for treating subjects with metabolic disorders and coronavirus infections |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2335597A (en) * | 1998-03-27 | 1999-09-29 | Glaxo Group Ltd | Stereoisomers of Troglitazone in the Treatment of Diabetes |
| US6127394A (en) * | 1999-03-08 | 2000-10-03 | The University Of Mississippi | 1,2-Dithiolane derivatives |
| GB9908647D0 (en) * | 1999-04-15 | 1999-06-09 | Smithkline Beecham Plc | Novel compounds |
| WO2002013812A1 (en) * | 2000-08-17 | 2002-02-21 | Pershadsingh Harrihar A | Methods for treating inflammatory diseases |
| WO2003045383A1 (en) * | 2001-11-26 | 2003-06-05 | Arachnova Therapeutics Ltd. | Use of ppar activators for the treatment of pulmonary fibrosis |
| US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| JP2005200419A (ja) * | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
| WO2007100027A1 (ja) * | 2006-03-02 | 2007-09-07 | Daiichi Sankyo Company, Limited | 光学活性なチアゾリジンジオン誘導体 |
-
2009
- 2009-08-05 CN CN200980140343.5A patent/CN102170864B/zh not_active Expired - Fee Related
- 2009-08-05 PT PT97848683T patent/PT2222272E/pt unknown
- 2009-08-05 JP JP2011521630A patent/JP5689797B2/ja not_active Expired - Fee Related
- 2009-08-05 DK DK09784868.3T patent/DK2222272T3/da active
- 2009-08-05 NZ NZ590774A patent/NZ590774A/xx not_active IP Right Cessation
- 2009-08-05 EP EP09784868A patent/EP2222272B1/en active Active
- 2009-08-05 BR BRPI0917567A patent/BRPI0917567A2/pt not_active IP Right Cessation
- 2009-08-05 PL PL09784868T patent/PL2222272T3/pl unknown
- 2009-08-05 CA CA2733440A patent/CA2733440C/en not_active Expired - Fee Related
- 2009-08-05 AU AU2009279077A patent/AU2009279077C1/en not_active Ceased
- 2009-08-05 SI SI200930499T patent/SI2222272T1/sl unknown
- 2009-08-05 ES ES09784868T patent/ES2399179T3/es active Active
- 2009-08-05 MX MX2011001418A patent/MX2011001418A/es active IP Right Grant
- 2009-08-05 GB GB1000468A patent/GB2465897B/en not_active Expired - Fee Related
- 2009-08-05 EA EA201100305A patent/EA019339B1/ru not_active IP Right Cessation
- 2009-08-05 WO PCT/GB2009/001920 patent/WO2010015818A1/en active Application Filing
-
2011
- 2011-01-28 ZA ZA2011/00750A patent/ZA201100750B/en unknown
- 2011-01-30 IL IL210959A patent/IL210959A0/en not_active IP Right Cessation
- 2011-10-11 HK HK11110728.5A patent/HK1156501A1/xx not_active IP Right Cessation
-
2013
- 2013-01-17 SM SM201300007T patent/SMT201300007B/xx unknown
- 2013-01-22 HR HRP20130052AT patent/HRP20130052T1/hr unknown
- 2013-02-06 CY CY20131100108T patent/CY1113744T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2222272E (pt) | 2013-01-29 |
| AU2009279077A1 (en) | 2010-02-11 |
| MX2011001418A (es) | 2011-07-20 |
| JP5689797B2 (ja) | 2015-03-25 |
| IL210959A0 (en) | 2011-04-28 |
| EP2222272A1 (en) | 2010-09-01 |
| WO2010015818A1 (en) | 2010-02-11 |
| SI2222272T1 (sl) | 2013-03-29 |
| GB2465897A (en) | 2010-06-09 |
| CA2733440A1 (en) | 2010-02-11 |
| CN102170864A (zh) | 2011-08-31 |
| EA019339B1 (ru) | 2014-02-28 |
| NZ590774A (en) | 2012-09-28 |
| ES2399179T3 (es) | 2013-03-26 |
| JP2011529953A (ja) | 2011-12-15 |
| AU2009279077C1 (en) | 2014-12-04 |
| PL2222272T3 (pl) | 2013-04-30 |
| CY1113744T1 (el) | 2016-06-22 |
| HK1156501A1 (en) | 2012-06-15 |
| DK2222272T3 (da) | 2013-02-11 |
| EP2222272B1 (en) | 2012-11-07 |
| BRPI0917567A2 (pt) | 2015-11-17 |
| CN102170864B (zh) | 2015-04-01 |
| EA201100305A1 (ru) | 2011-10-31 |
| SMT201300007B (it) | 2013-03-08 |
| AU2009279077B2 (en) | 2014-07-03 |
| GB2465897B (en) | 2011-02-09 |
| CA2733440C (en) | 2016-06-28 |
| ZA201100750B (en) | 2012-06-27 |
| GB201000468D0 (en) | 2010-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130052T1 (hr) | Lijeäśenje respiratorne bolesti | |
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2012503668A5 (hr) | ||
| HRP20201150T1 (hr) | Inhalacija levofloksacina za smanjenje upale pluća | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| HRP20120286T1 (hr) | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti | |
| JP2022180461A5 (hr) | ||
| JP2010518122A5 (hr) | ||
| CL2009000601A1 (es) | Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis. | |
| PT1326595E (pt) | Composicao farmaceutica compreendendo resveratrol para o tratamento de disturbios respiratorios inflamatorios | |
| HRP20160373T1 (hr) | Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava | |
| JP2013224331A5 (hr) | ||
| HRP20151214T4 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti | |
| MX2019006938A (es) | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. | |
| JP2008502699A5 (hr) | ||
| JP2008533072A5 (hr) | ||
| JP2011530493A5 (hr) | ||
| JP2020516689A5 (hr) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2019517541A5 (hr) | ||
| MX2018014425A (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| JP2008502698A5 (hr) | ||
| JP2011012060A5 (hr) |